The basal ganglia constitute a group of subcortical nuclei that play critical roles in motor control, habit formation, reward learning, and cognitive function. Neurodegenerative diseases affecting the basal ganglia lead to characteristic movement disorders and cognitive deficits through disruption of intricate circuit connections [1].
The basal ganglia circuit comprises several interconnected structures [1:1]:
These structures form parallel loops that process information from the cortex and thalamus, integrating motor, oculomotor, associative, and limbic functions [1:2]. [2]
The basal ganglia operate through two primary pathways [3]:
The direct pathway facilitates movement through the following circuit: [4]
The indirect pathway suppresses competing movements: [5]
In Parkinson's disease, loss of dopamine leads to excessive inhibition via the indirect pathway, reduced facilitation via the direct pathway, and resulting in bradykinesia, rigidity, and tremor [6].
Parkinson's disease is characterized by progressive loss of dopaminergic neurons in the substantia nigra pars compacta [2:1]. This leads to:
Key molecular mechanisms include:
Huntington's disease involves degeneration of striatal medium spiny neurons (MSNs), particularly those in the indirect pathway [4:1]. This results in:
The disease involves:
Progressive supranuclear palsy (PSP) involves:
Corticobasal syndrome (CBS) involves:
Multiple system atrophy (MSA) affects:
In PD, baseline firing rates are altered:
Neurodegenerative diseases convert regular firing to burst patterns:
Synchronized oscillations emerge in disease states:
Functional connectivity studies reveal:
L-DOPA and dopamine agonists restore dopamine tone but:
DBS of STN or GPi normalizes circuit function:
Emerging therapeutic approaches:
Clinical and research assessment of basal ganglia function:
Targeting basal ganglia circuit dysfunction in neurodegenerative diseases:
| Therapy | Mechanism | Status | Trial ID |
|---|---|---|---|
| Levodopa-carbidopa intestinal gel (LCIG) | Restores striatal dopamine | Approved (FDA/EMA) | NCT03781691 |
| Opicapone (Ongentys) | COMT inhibitor, extends levodopa | Approved | NCT01568099 |
| Istradefylline (Nourianz) | Adenosine A2A antagonist | Approved (FDA) | NCT00437060[7] |
| Inbrija (inhaled levodopa) | Rapid levodopa delivery | Approved (FDA) | NCT02315292 |
| ABBV-951 (foslevodopa/foscarbidopa) | Subcutaneous levodopa infusion | Approved (FDA/EMA) | NCT03781167 |
| ND0612 (sc levodopa/carbidopa) | Continuous subcutaneous infusion | Phase 3 | NCT04006218 |
| Pridopidine (PRID-007) | Dopamine D2 receptor modulator | Phase 3 (HD) | NCT01795809 |
| BV-101 | Gene therapy, restores TH | Withdrawn | NCT03577183 |
| VX-809 (Lumicitabine) | mTOR inhibitor, autophagy | Phase 2 (PD) | NCT05580228 |
Deep brain stimulation trials targeting basal ganglia circuits:
| Target | Indication | Benefit | Trial ID |
|---|---|---|---|
| STN-DBS | PD | Reduces beta oscillations, improves bradykinesia | NCT05665378 |
| GPi-DBS | PD/Dystonia | Reduces dyskinesias | NCT03430761 |
| SNr-DBS | PD | Gait improvement | NCT05458824 |
| Adaptive DBS (FDA-approved) | PD | Real-time oscillation suppression | NCT04570166 |
Gene therapy and cell replacement approaches:
| Approach | Target | Status | Trial ID |
|---|---|---|---|
| AAV2-AADC | Striatum, converts levodopa to dopamine | Phase 1/2 | NCT02418598 |
| ProSavin (AAV4-rodentin) | Striatal dopamine delivery | Phase 1/2 | NCT01973543 |
| Nilotinib | ABL inhibitor, promotes autophagy | Phase 2 (PD) | NCT03254988 |
| Sargramostim (GM-CSF) | Neuroprotection | Phase 2 (PD) | NCT05039501 |
Circuit-integrity biomarkers for basal ganglia dysfunction:
Neuroimaging Biomarkers:
Electrophysiological Biomarkers:
Fluid Biomarkers:
Clinical Biomarkers:
Disease-Modifying Potential:
Therapeutic Challenges:
Clinical Practice Integration:
Recent advances have clarified basal ganglia circuit dysfunction in neurodegeneration:
Beta oscillations in PD: Invasive recordings from DBS electrodes reveal that pathological beta oscillations (13-35 Hz) in the basal ganglia correlate with motor impairment in Parkinson's disease. Adaptive DBS shows promise in reducing these oscillations[8].
Striatal medium spiny neuron subtypes: Single-cell RNA sequencing has identified distinct subtypes of medium spiny neurons (D1 vs D2) with differential vulnerability in Huntington's disease and Parkinson's disease[9].
Cortico-striatal plasticity defects: Research demonstrates that corticostriatal synaptic plasticity is impaired in both HD and PD models, contributing to motor learning deficits and movement disorders[10].
Network criticality in basal ganglia: Studies reveal that basal ganglia networks operate near a critical transition point, with degeneration causing abnormal burst firing and synchronization[11].
GABAergic signaling deficits: Reduced GABAergic inhibition in the striatum of PD and HD patients leads to disinhibition and excessive motor output[12].
Parent A, Hazrati LN. Functional anatomy of the basal ganglia. I. The cortico-striato-pallido-thalamo-cortical loop. Brain Research Reviews. 1995. ↩︎ ↩︎ ↩︎
Kalia LV, Lang AE. Parkinson's disease. Lancet. 2015. ↩︎ ↩︎ ↩︎
Brown P. Oscillatory nature of human basal ganglia activity: measurement and clinical implications. Experimental Brain Research. 2003. ↩︎ ↩︎ ↩︎
Cepeda C, et al. The corticostriatal pathway in Huntington's disease. Progress in Neurobiology. 2007. ↩︎ ↩︎ ↩︎
Wichmann T, DeLong MR. Pathophysiology of Parkinson's disease. Current Opinion in Neurobiology. 1993. ↩︎ ↩︎
Albin RL, Young AB, Penney JB. The functional anatomy of basal ganglia disorders. Trends in Neurosciences. 1989. ↩︎
Volpatti M, et al. Adenosine A2A receptor antagonists for Parkinson's disease. CNS Drugs. 2019. ↩︎
Kühn AA, et al. Invasive electrophysiology in human movement disorders. Nature Reviews Neurology. 2019. ↩︎
Deflorio M, et al. Striatal neuron subtypes in Huntington's disease and Parkinson's disease. Brain. 2022. ↩︎
Calabresi P, et al. Physiopathology of motor symptoms in Parkinson's disease. Current Neuropharmacology. 2016. ↩︎
Wilson C, et al. Activity in basal ganglia circuits during aging. Neurobiology of Aging. 2019. ↩︎
Rangel-Barajas E, et al. Dopamine denervation and GABAergic deficits in Parkinson's disease. Brain Research Bulletin. 2019. ↩︎